Funder: National Institutes of Health
Due Dates: June 6, 2023 | June 6, 2024 | June 6, 2025 | October 6, 2025
Funding Amounts: Phase I: up to $295,924 (1 year); Phase II: up to $1,972,828 (2 years); higher budgets may be allowed for waiver topics.
Summary: Supports U.S. small businesses developing novel extracellular vesicle-based therapeutic platforms for regenerative medicine, focused on production, manufacturing, and use of EVs as therapeutics.
Key Information: Clinical trials are not allowed; only U.S. small businesses are eligible; foreign institutions cannot apply.